Peto writes that "any competent trial statistician" would back his conclusions and says that Vytorin's makers, Merck and Schering-Plough, do not pay his salary and had no impact on the decision to conduct his analysis or on how the analysis was conducted (see Peto's letter).

FORBES: Magazine Article

Peto serves as statistician for one Vytorin trial, but does not receive direct money from Merck and Schering-Plough.

FORBES: Magazine Article

Eugene Braunwald, a prominent Harvard cardiologist who is running a Vytorin trial, called Peto "the best statistician in the universe" while telling reporters that any cancer risk with the drug is unlikely.

FORBES: Magazine Article